Clinical trials: SCD, active
Sudden Cardiac Death
Dilated Cardiomyopathy - Unknown Therapeutic Risk Reduction by Contempary Medication and Implantable Cardioverter-Defibrillators (DUTCH-ICD)
Research questions: The value of primary prevention implantable cardioverter-defibrillator implantation (ICD) therapy in patients with non-ischemic cardiomyopathy (NICM) is under debate.
- Trial name
- DUTCH-ICD (NCT07415642)
- Testing
- ICD implantation
- Where
- 2 sites in Netherlands
- Volunteers
- 720 people
- Sponsor
- University Medical Center Groningen
Sudden Cardiac Death
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
The PROTECT-ICD trial is a physician-led, multi-centre randomised controlled trial targeting prevention of sudden cardiac death in patients who have poor cardiac function following a myocardial infarct (MI).
- Trial name
- PROTECT-ICD (NCT03588286)
- Testing
- Electrophysiology study (EPS), Standard Care, Cardiac Magnetic Resonance (CMR)
- Where
- 52 sites in United States, Australia and 13 more
- Volunteers
- 1,058 people
- Sponsor
- Western Sydney Local Health District
Ventricular Tachycardia, Sudden Cardiac Death
Functional Substrate-Only Guided VT Ablation
Ventricular tachycardia (VT) is a leading cause of death and suffering in the Veteran population. Currently, ablation procedures are performed to destroy the diseased tissue that causes this problem.
- Trial name
- SLO-VT (NCT06464315)
- Testing
- Functional Substrate-Only Mapping without VT Induction, Standard-of-Care Mapping/Imaging
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- VA Office of Research and Development
Pain, Sickle Cell Disease
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
The study, known as the Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy (PRESENCE), aims to determine the effectiveness of digital CBT in reducing pain…
- Trial name
- PRESENCE (NCT06374238)
- Testing
- CBT+ Health coach, CBT w/o Health Coach ( self-guided), Usual Care
- Where
- 14 sites in United States
- Volunteers
- 390 people
- Sponsor
- University of Pittsburgh
Arrhythmogenic Cardiomyopathy, PKP2-ACM
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.
- Conditions
- Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
- Trial name
- SNAPSHOT- PKP2 (NCT06976606)
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Lexeo Therapeutics
Sickle Cell Trait, Sickle Cell Disease (SCD)
Sickle Cell Kidney Biorepository
Kidney disease is a major cause of illness and death in people with sickle cell disease and sickle cell trait. Despite these concerning facts, we do not (1) have an in-depth understanding of how kidney disease starts in sickle…
- Conditions
- Sickle Cell Trait, Sickle Cell Disease (SCD), Chronic Kidney Disease
- Trial name
- SCeK (NCT07064174)
- Where
- 2 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype…
- Trial name
- TaRGET (NCT06174220)
- Testing
- Tideglusib
- Where
- 17 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Hamilton Health Sciences Corporation
Insomnia Chronic, Subjective Cognitive Decline (SCD)
Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Insomnia with Subjective Cognitive Decline
Insomnia is the most common form of sleep disorder, and subjective cognitive decline (SCD) in patients with insomnia may be an ultra-early manifestation of AD.
- Trial name
- NCT06710652
- Testing
- rTMS
- Volunteers
- 66 people
- Sponsor
- Fujian Medical University Union Hospital
Sickle Cell Anemia
Haploidentical PBMC Transplant for Severe Congenital Anemias
Background: Bone marrow transplantation (BMT), which involves transplanting a donor's marrow stem cells, is capable of curing some congenital anemias.
- Trial name
- NCT00977691
- Testing
- PBSC Transplant, Alemtuzumab, Sirolimus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Blood and Lymphatic Diseases
Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
Primary Objectives: Long-term safety of BIVV003 in participants with severe sickle cell disease (SCD) and ST- 400 in participants with transfusion-dependent beta-thalassemia (TDT) Secondary Objectives: Long-term efficacy of the…
- Trial name
- NCT05145062
- Testing
- BIVV003, ST-400
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sangamo Therapeutics
Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia, Mantle Cell Lymphoma, Sudden Cardiac Death
- Trial name
- NCT05724121
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects ≥2 and ≤50 years of age with sickle cell disease (SCD).
- Trial name
- NCT04293185
- Testing
- bb1111
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- Genetix Biotherapeutics Inc.
Sickle Cell Disease, Pregnancy Related
Sickle Cell Disease Obstetric Multi-Disciplinary Care Programme
To implement an effective but low-cost strategy to decrease SCD maternal and perinatal mortality in Ghana. The objectives are to 1) assess the impact of a multidisciplinary SCD-obstetric team for decreasing mortality across three…
- Trial name
- SCOB-II (NCT05143021)
- Testing
- Multidisciplinary Sickle Cell Disease- Obstetric Team
- Where
- 3 sites in Ghana
- Volunteers
- 500 people
- Sponsor
- Vanderbilt University Medical Center
Sickle Cell Disease, Cognitive Impairment
Minocycline In Neurocognitive Outcomes - Sickle Cell Disease
Sickle cell disease (SCD) is a common, inherited blood disorder that primarily affects people of African Ancestry. It has a lot of complications including neurological complications.
- Conditions
- Sickle Cell Disease, Cognitive Impairment, Cognitive Decline, Cognitive Change
- Trial name
- MINO-SCD (NCT05605366)
- Testing
- Minocycline
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome
Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD).
- Conditions
- Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome, Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), Long QT Syndrome (LQTS)
- Trial name
- HiRO (NCT04189822)
- Where
- Canada
- Volunteers
- 10,000 people
- Sponsor
- University of British Columbia
Acute Coronary Syndrome Without ST Elevation on Electrocardiogram, Acute Coronary Syndromes (ACS)
Occurrence of Severe Cardiac Rhythm and Conduction Disturbances in Emergency Department Patients With Non-ST Elevation Acute Coronary Syndrome
Cardiovascular diseases are the leading cause of death worldwide. Among them, coronary artery disease-especially in its acute form, known as acute coronary syndrome (ACS)-is the most frequent cause of cardiovascular death.
- Conditions
- Acute Coronary Syndrome Without ST Elevation on Electrocardiogram, Acute Coronary Syndromes (ACS), Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease
- Trial name
- SurvSCA (NCT07112547)
- Where
- 10 sites in France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
Myocardial Bridge of Coronary Artery, Myocardial Bridge
Myocardialbridge Bypass Graft Surgery Efficacy Verification
Myocardial Bridge Bypass Graft surgery is introduced to relieve the unmedical symptoms of patients with long-segment or deep myocardial bridge, clinical outcomes will be collected to verify the effectiveness of the surgery.
- Conditions
- Myocardial Bridge of Coronary Artery, Myocardial Bridge, Myocardial Bridging, Myocardial Infarction
- Trial name
- NCT06857838
- Testing
- MBBG, MB CABG, MB unroof
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xi'an International Medical Center Hospital
Arrhythmogenic Right Ventricular Cardiomyopathy, FAPI PET
FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease associated with fibrofatty myocardial replacement, ventricular arrhythmias, and an increased risk of sudden cardiac death.
- Conditions
- Arrhythmogenic Right Ventricular Cardiomyopathy, FAPI PET, Cardiac Magnetic Resonance Imaging
- Trial name
- FAPI-ARVC (NCT07563660)
- Testing
- 68Ga-DOTA-SA-FAPI PET/CT
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Istanbul University - Cerrahpasa
in Relation to Sickle Cell Disease
Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"
Evaluation of AHSP concentration in total blood as a biomarker in adult and pediatric sickle cell patients
- Trial name
- AHSPDREP (NCT06735625)
- Testing
- Measurement of AHSP concentration
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier de Saint-Denis
Sickle Cell Disease
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
The goal of this short term prospective Phase II study is to compare the effects of two alternate daily doses of zinc (25 and 40 mg/day) in 34 randomly assigned homozygous Sickle Cell Disease (SCD-SS) patients aged 15-40 years…
- Trial name
- ZnSCD (NCT06260891)
- Testing
- 25 mg/day zinc, 40 mg/day zinc
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Francisco